MedTrace Logo

Pharmacokinetic Study of Testosterone Enanthate

NCT01887418 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2018-01-11

Study results available
· View outcomes & findings →

Summary

Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.

Conditions

  • Hypogonadism

Interventions

DRUG

QuickShot™ - 50 mg Treatment B

QuickShot™ for the delivery of testosterone

DRUG

QuickShot™ - 100 mg Treatment A

QuickShot™ for the delivery of testosterone

DRUG

Delatestryl 200 mg IM Treatment C

Standard of care

Sponsors & Collaborators

  • Antares Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Gary Bedel, MD · Prestige Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01887418 on ClinicalTrials.gov